Durability of Immunogenicity and Effectiveness of the heterologous COVID-19 vaccination in kidney transplant recipients

Durability of Immunogenicity and Effectiness of the heterologous COVID-19 vaccination in kidney transplant recipients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220511002

Enrollment

100

Registered

2022-05-11

Start date

2022-04-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunogenicity of the vaccine Effectiveness of the vaccine humoral immunity, cell-mediated immunity, SARS-CoV-2, immunization, immunocompromised

Interventions

Immunogenicity and effectiveness

Experimental Drug

CVIM5

Eligibility

Sex/Gender

All

Age

18 Years to 59 Years

Inclusion criteria

Inclusion criteria: Patients were all recruited from the previous studies (CVIM1, CVIM2, CVIM3 and CVIM 4)

Exclusion criteria

Exclusion criteria: Those who declined to participate in the study

Design outcomes

Primary

Measure	Time frame
Immunogenecity at 6 months after vaccination Humoral and cell-mediated immunity	—

Secondary

Measure	Time frame
Effectiveness within 6 months Rate of COVID-19 diagnosis	—

Countries

Thailand

Contacts

Public ContactJackrapong Bruminhent

Faculty of Medicine Ramathibodi Hospital

jackrapong.brm@mahidol.ac.th6622011582

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026